A phase 1b, open-label, safety, pharmacokinetic, and pharmacodynamic study of an anti-super-enhancer triptolide analogue with nab-paclitaxel plus gemcitabine in patients with metastatic adenocarcinoma of the pancreas.

被引：0
|
作者：
Park, Joon Oh
Hong, Jung Yong
Kim, Seung Tae
Park, Young Suk
Saluja, Ashok
机构：
[1] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[2] Univ Miami, Dept Surg, Sylvester Comprehens Canc Ctr, Miami, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS769
引用
收藏
页码：TPS769 / TPS769
页数：1
相关论文
共 50 条
  • [41] Evaluation of peripheral neuropathy in a phase Ill trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients with metastatic adenocarcinoma of the pancreas
    Goldstein, D.
    Von Hoff, D. D.
    Moore, M.
    Greeno, E.
    Ritch, P.
    Tortora, G.
    Ramanathan, R. K.
    Tabernero, J.
    Ko, A.
    Lu, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S613 - S613
  • [42] Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study
    Dean, Andrew
    Gill, Sanjeev
    McGregor, Mark
    Broadbridge, Vy
    Jarvelainen, Harri A.
    Price, Timothy
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (10): : 943 - 951
  • [43] A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
    Chang, Chen
    Li, Xiaofen
    Cheng, Ke
    Cai, Zhaolun
    Xiong, Junjie
    Lv, Wanrui
    Li, Ruizhen
    Zhang, Pei
    Cao, Dan
    ONCOLOGIST, 2023, 28 (07): : E575 - E584
  • [44] Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2-positive metastatic pancreatic cancer (mPC).
    Park, Wungki
    O'Reilly, Eileen Mary
    Furuse, Junji
    Kunieda, Futoshi
    Jie, Fei
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
    Wainberg, Zev A.
    Bekaii-Saab, Tanios S.
    Hubner, Richard
    Macarulla, Teresa
    Paulson, Andrew Scott
    Van Cutsem, Eric
    Maxwell, Fiona
    Moore, Yan
    Wang, Haofei Tiffany
    Zhang, Bin
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Jaime Feliu
    Mónica Jorge Fernández
    Teresa Macarulla
    Bartomeu Massuti
    Ana Albero
    José Federico González González
    Guillermo Quintero-Aldana
    Juan Ignacio Delgado-Mingorance
    Ana Fernández Montes
    Carmen García Piernavieja
    Manuel Valladares-Ayerbes
    Ana María López Muñoz
    Rebeca Mondéjar Solís
    Pilar Vicente
    Esther Casado Gonzalez
    Irene González Cebrián
    Guillermo López-Vivanco
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 543 - 553
  • [47] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Feliu, Jaime
    Jorge Fernandez, Monica
    Macarulla, Teresa
    Massuti, Bartomeu
    Albero, Ana
    Gonzalez Gonzalez, Jose Federico
    Quintero-Aldana, Guillermo
    Ignacio Delgado-Mingorance, Juan
    Fernandez Montes, Ana
    Garcia Piernavieja, Carmen
    Valladares-Ayerbes, Manuel
    Lopez Munoz, Ana Maria
    Mondejar Solis, Rebeca
    Vicente, Pilar
    Casado Gonzalez, Esther
    Gonzalez Cebrian, Irene
    Lopez-Vivanco, Guillermo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (04) : 543 - 553
  • [48] A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
    Davis, S. Lindsey
    Cardin, Dana B.
    Shahda, Safi
    Lenz, Heinz-Josef
    Dotan, Efrat
    O'Neil, Bert H.
    Kapoun, Ann M.
    Stagg, Robert J.
    Berlin, Jordan
    Messersmith, Wells A.
    Cohen, Steven J.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 821 - 830
  • [49] A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
    S. Lindsey Davis
    Dana B. Cardin
    Safi Shahda
    Heinz-Josef Lenz
    Efrat Dotan
    Bert H. O’Neil
    Ann M. Kapoun
    Robert J. Stagg
    Jordan Berlin
    Wells A. Messersmith
    Steven J. Cohen
    Investigational New Drugs, 2020, 38 : 821 - 830
  • [50] An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update.
    Brezden, C. B.
    Cantin, G.
    Younus, J.
    Panasci, L. C.
    Klimo, P.
    Laing, K. E.
    Raymond, N.
    Lam, W.
    Trudeau, M. E.
    Robidoux, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345